# Cisplatin - Esophageal neoplasm metastatic

## 1. Case Metadata

- pair_id: `repodb_0ee62470d8ffb2ae`
- drug: Cisplatin
- disease: Esophageal neoplasm metastatic
- repoDB label: `negative_or_failed`
- full pipeline prediction: `positive`
- full confidence score: 0.8
- full status: `completed`
- case type: `incorrect_but_informative`
- manual review status: `TODO_MANUAL_REVIEW`

## 2. Why This Case Was Selected

Meets selection criteria for incorrect_but_informative. The case is included for manual review, not as a definitive biomedical conclusion.

## 3. Evidence Summary

### 3.1 PubMed Evidence

- PMIDs available in PubMed baseline: 59
- PMIDs used by full pipeline: 60
- Abstract availability rate from baseline: 1

Top available PMID/title rows:

- PMID `34519801` (2021): Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous...
- PMID `40215279` (2025): FAO-fueled OXPHOS and NRF2-mediated stress resilience in MICs drive lymph node metastasis.
- PMID `33975465` (2021): KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
- PMID `39511164` (2024): First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study.
- PMID `34160577` (2021): Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 R...

The literature signal should be interpreted as co-mention and retrieved-document support. It does not establish efficacy.

### 3.2 Open Targets Evidence

- drug resolved: yes
- disease resolved: yes
- disease targets: 100
- drug targets: 0
- overlapping targets: 0
- support score: 0

Open Targets support is target-evidence context, not clinical truth.

### 3.3 PrimeKG Graph Evidence

- drug mapped: yes
- disease mapped: no
- graph path exists: no
- shortest path length: 0
- graph connectivity score: 0

Graph paths:

- No graph path rows available for this pair.

PrimeKG connectivity is mechanism support only and does not prove efficacy.

### 3.4 Full-Agent Generated Report

Conclusion field: `Potential`. Short summary: Cisplatin is a standard first-line treatment for advanced esophageal cancer, but resistance is a significant clinical challenge. Several studies explore mechanisms of cisplatin resistance and strategies to overcome it, including targeting specific miRNAs and pathways. While direct evidence for repurposing cisplatin is limited as it's already in use, research focuses on enhancing its efficacy and overcoming resistance.

### 3.5 Claim Verification

- claims: 4
- verified claims: 1
- unsupported claims: 2
- citation verified rate: 0.25
- unsupported claim rate: 0.5

Claim examples:

- `VERIFIED` claim: Cisplatin is a standard treatment for advanced esophageal cancer, but resistance is a major issue. PMIDs: 38494800, 36995552, 37672204, 37401860, 38251697
- `PARTIALLY_VERIFIED` claim: Dysregulation of specific miRNAs contributes to cisplatin resistance in esophageal cancer. PMIDs: 36995552, 34277424, 37401860, 38251697
- `UNVERIFIED` claim: FAM111B promotes esophageal cancer tumorigenesis and cisplatin resistance by degrading GSDMA. PMIDs: 37672204
- `UNVERIFIED` claim: Cordycepin enhances cisplatin sensitivity in esophageal cancer by activating AMPK and suppressing AKT signaling. PMIDs: 33067427

## 4. Manual Interpretation

The available evidence suggests a research-support assessment only. The retrieved literature and structured evidence may be consistent with the full-agent assessment, but this case does not establish efficacy, safety, or clinical utility. Any apparent alignment or mismatch with the repoDB proxy label requires expert review of the original repoDB row, PubMed abstracts, Open Targets mappings, and graph paths.

## 5. Error Analysis Or Reliability Analysis

This case is useful for `incorrect_but_informative`. It shows how OrphanCure preserves provenance, exposes missing evidence, and separates report faithfulness from repoDB label prediction. If the prediction is incorrect or partial, the case should be used to study failure modes rather than to claim biomedical validity.

## 6. Interview Talking Points

- 30-second explanation: This case shows how OrphanCure turns a drug-disease pair into a traceable evidence report with PubMed, Open Targets, graph, and verifier outputs.
- 2-minute explanation: Discuss the repoDB proxy label, what evidence layers were available, whether the generated claims were verified, and why this does or does not align with the label.
- Technical takeaway: The case keeps `pair_id`, evidence availability, claims, and verification status tied together.
- Limitation: Evidence grounding is not the same as clinical validation.

## 7. Safety Note

This case study is for research and educational purposes only. It is not medical advice and must not be used for clinical decision-making.

## 8. Manual Review Checklist

- [ ] repoDB row checked
- [ ] PubMed PMIDs checked
- [ ] Abstracts checked
- [ ] Open Targets mappings checked
- [ ] PrimeKG paths checked
- [ ] Generated claims checked
- [ ] Citations checked
- [ ] Biomedical expert review completed
